Even though the clinical efficacy of antibody-based therapeutics has been established, no methods that involve the de novo design of antibodies with wet lab validation are available.
About the study
A recent study, posted in the bioRxiv* preprint server, used generative AI models to develop de novo design antibodies against three distinct targets in a zero-shot fashion. A zero-shot designing method involves designing an antibody to bind to an antigen without follow-up optimization. The newly designed process has been termed de novo, meaning proteins (antibodies) were designed from first principles or from scratch.
Comments are closed.